Focus on European Funding Christian Delles BHF Glasgow Cardiovascular Research Centre Institute of Cardiovascular and Medical Sciences University of Glasgow

European Funding Systems Biology to Identify Molecular Targets for Vascular Disease Treatment Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria. Identification of the MOlecular DEterminants of established Chronic Kidney Disease Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies Markers for Sub-Clinical Cardiovascular Risk Assessemnt

The New EU Framework Programme for Research and Innovation HORIZON 2020 Telemachos TELEMACHOU DG Research & Innovation European Commission

For further information Participant Portal Helpdesk Expert evaluators needed! Learn more about Horizon Thank you for your attention!

The Multiannual Financial Framework : Key challenge: stabilise the financial and economic system while taking measures to create economic opportunities 1. Smart & inclusive growth (€451 billion) 2. Sustainable growth, natural resources (€373 billion) 3. Security and citizenship (€16 billion) 4. Global Europe (€58 billion) 5. Administration (€61.6 billion) (figures are given in constant prices) Education, Youth, Sport Connecting Europe Cohesion Competitive Business SMEs HORIZON 2020 TOTAL €960 billion

What is Horizon 2020 The new European Union programme for research and innovation for A budget of just over €79 billion; 30 per cent higher in real terms than the period A core part of Europe 2020, Innovation Union & European Research Area: − Responding to the economic crisis to invest in jobs and growth − Addressing people’s concerns about their livelihoods, safety and environment − Strengthening the EU’s global position in research, innovation and technology 6

€ 79 billion from 2014 to 2020

What's new An integrated programme coupling research to innovation – support from research to retail, bringing together three separate programmes/initiatives* Challenge based - tackling major challenges facing EU society, e.g. health, clean energy and transport Strong focus on SMEs Open to the rest of the world Major simplification - for all companies, universities, institutes in all EU countries and beyond  The 7 th Research Framework Programme (FP7), innovation aspects of Competitiveness and Innovation Framework Programme (CIP), EU contribution to the European Institute of Innovation and Technology (EIT) 8

Three priorities Excellent science Industrial leadership Societal challenges 9

Strong focus on SMEs In collaborative projects - 20% of total budget for societal challenges and enabling & industrial technologies to go to SMEs A new SME instrument in all societal challenges and enabling & industrial technologies (7% of relevant budgets) Simplification of particular benefit to SMEs (e.g. single entry point) Eurostars joint programme with Member States and associated countries for research-intensive SMEs Access to risk finance to have a strong SME focus - (debt and equity facilities) 10

Major Simplification for the benefit of applicants 1.A single set of rules for all funding under Horizon 2020 Fewer, more flexible, funding instruments 2.Simpler reimbursement: 1 project = 1 funding rate 100% of the total eligible costs (70% for innovation actions) Non-profit legal entities can also receive 100% in innovation actions Single flat rate for indirect costs (25% of eligible costs) 3.Faster time to grant Within 8 months of call deadline

Evaluation criteria Proposal evaluated by the experts “as it is” and not as “what could be” = no need for negotiation Innovation actions higher weighting for "IMPACT" STANDARD AWARD CRITERIA QUALITY & EFFICIENCY OF THE ACTION QUALITY & EFFICIENCY OF THE ACTION IMPACT EXCELLENCE ERC frontier Research actions only EXCELLENCE

Call Text : Evaluation and validation studies of clinically useful biomarkers in prevention and management of cardiovascular diseases. Two-stage. Existing and emerging biomarkers and related mechanisms should be exploited to improve identification, risk assessment, clinical decision making and clinical outcomes. Cost effectiveness, safety, validity and incremental benefit over existing risk prediction methods and life style determinants of investigated biomarkers must be demonstrated. The impact of biomarkers on cardiovascular disease risk prediction will need to be assessed across different European populations as they have different lifestyles (e.g. dietary patterns) and varying biomarker levels. Multidisciplinary research consortia must use state-of-the-art translational research, epidemiological and diagnostic technology (such as imaging technology) and knowledge. Note: Limits on the EU financial contribution apply. These are implemented strictly as formal eligibility criteria. Funding scheme: SME-targeted Collaborative Project. Requested EU contribution per project: Maximum EUR One or more proposals can be selected. Expected impact: Assessment of cardiovascular risk in individuals is complementary to public health activities that aim to reduce the overall population risk of cardiovascular disease by promoting a healthy lifestyle (diet, exercise, avoidance of smoking). The results of research should lead to improved cardiovascular risk prediction and contribute to the development of personalised and predictive medicine. Specific feature: SME-targeted research is designed to encourage SME efforts towards research and innovation. Priority will be given to proposals demonstrating that research intensive SMEs play a leading role. The projects will be led by SMEs with R&D capacities, but the coordinator does not need to be an SME. The expected project results should clearly be of interest and potential benefit to SME(s). Additional eligibility criterion: SME-targeted Collaborative Projects will only be selected for funding on the condition that the estimated EU contribution going to SME(s) is 30-50% or more of the total estimated EU contribution for the project as a whole. This will be assessed at the end of the negotiation, before signature of the grant agreement. Proposals not fulfilling this criterion will not be funded.

Partners Participant no. Participant organisation name Participant short name Country 1 (CO)University of GlasgowGLA United Kingdom 2Medical University of GrazGRAAustria 3Emergentec Biodevelopment GmbHEMGAustria 4University of LeuvenLEUBelgium 5Medizinische Hochschule HannoverMHHGermany 6Charité, University BerlinCHAGermany 7Mosaiques Diagnostics GmbHMOSGermany 8Istituto Auxologico ItalianoAUXItaly 9University of Milan-BicoccaMIBItaly 10University of MaastrichtUMANetherlands 11ACS BiomarkerACSNetherlands 12Fundacíon Investigacíon Médica ApplicadaFIMASpain 13Fundacíon Investigacíon Biomédica, ValenciaFIHCUVSpain 14Randox Testing ServicesRTS United Kingdom 15Kite Innovation (Europe) LimitedKITE United Kingdom

Partners Participant no. Participant organisation name Participant short name Country 1 (CO)University of GlasgowGLA United Kingdom 2Medical University of GrazGRAAustria 3Emergentec Biodevelopment GmbHEMGAustria 4University of LeuvenLEUBelgium 5Medizinische Hochschule HannoverMHHGermany 6Charité, University BerlinCHAGermany 7Mosaiques Diagnostics GmbHMOSGermany 8Istituto Auxologico ItalianoAUXItaly 9University of Milan-BicoccaMIBItaly 10University of MaastrichtUMANetherlands 11ACS BiomarkerACSNetherlands 12Fundacíon Investigacíon Médica ApplicadaFIMASpain 13Fundacíon Investigacíon Biomédica, ValenciaFIHCUVSpain 14Randox Testing ServicesRTS United Kingdom 15Kite Innovation (Europe) LimitedKITE United Kingdom

Partners Participant no. Participant organisation name Participant short name Country 1 (CO)University of GlasgowGLA United Kingdom 2Medical University of GrazGRAAustria 3Emergentec Biodevelopment GmbHEMGAustria 4University of LeuvenLEUBelgium 5Medizinische Hochschule HannoverMHHGermany 6Charité, University BerlinCHAGermany 7Mosaiques Diagnostics GmbHMOSGermany 8Istituto Auxologico ItalianoAUXItaly 9University of Milan-BicoccaMIBItaly 10University of MaastrichtUMANetherlands 11ACS BiomarkerACSNetherlands 12Fundacíon Investigacíon Médica ApplicadaFIMASpain 13Fundacíon Investigacíon Biomédica, ValenciaFIHCUVSpain 14Randox Testing ServicesRTS United Kingdom 15Kite Innovation (Europe) LimitedKITE United Kingdom

Key Aims 1. To validate the association of emerging biomarkers with cardiovascular phenotypes in cross-sectional disease and population cohorts 2. To validate emerging biomarkers as predictors of changes in cardiovascular phenotypes and cardiovascular events in prospective disease and population cohorts 3. Integration of emerging biomarkers reflecting different aspects of pathophysiology with established biomarkers into a common predictive model 4.Development of novel diagnostic test strategies to improve clinical management of patients with cardiovascular diseases

Work Packages

Integration

Systems Medicine and Omics Technology DNA mRNA Protein Metabolites small molecules Proteomics Metabolomics Genomics Transcriptomics miRNAs

Systems Medicine: Data Integration Genome genetic variation Transcriptome RNA profiling Transcriptome miRNA profiling Metabolome small molecules Proteome gene products Risk factors Environment Modified from Levy D, CHBPR 2010 Data Integration

The concept linking processes, biomarker, and targets/drugs patient 1patient 2 process Aprocess B biomarker a biomarker b slow disease progression responders to therapy X fast disease progression responders to therapy Y Goal is to identify all processes p i characterizing the phenotype which we can probe by the biomarkers b i, from there selecting target/drug t i, d i.

Challenges in Academic – Industry Collaboration Different language Different concepts of “exploitation” Different work patterns Different employment structures Different financial resources